Compare WLK & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLK | NBIX |
|---|---|---|
| Founded | 1986 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 13.2B |
| IPO Year | 2004 | 1996 |
| Metric | WLK | NBIX |
|---|---|---|
| Price | $93.57 | $160.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 22 |
| Target Price | $106.87 | ★ $180.91 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 1.91 |
| Revenue | ★ $11,170,000,000.00 | $161,626,000.00 |
| Revenue This Year | $5.51 | $24.73 |
| Revenue Next Year | $3.74 | $13.14 |
| P/E Ratio | ★ N/A | $84.44 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $56.33 | $117.84 |
| 52 Week High | $124.23 | $161.77 |
| Indicator | WLK | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 31.65 | 79.51 |
| Support Level | $91.76 | $125.54 |
| Resistance Level | $103.00 | N/A |
| Average True Range (ATR) | 3.85 | 4.41 |
| MACD | -2.00 | 2.94 |
| Stochastic Oscillator | 4.53 | 94.60 |
Westlake Corp is a vertically integrated international manufacturer and marketer of both housing and infrastructure products and performance and essential materials that are designed to enhance the lives of people every day. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and international compounds businesses.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.